Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.
Mol Cell Proteomics. 2021;20:100116. doi: 10.1016/j.mcpro.2021.100116. Epub 2021 Jun 17.
Immunotherapies have emerged to treat diseases by selectively modulating a patient's immune response. Although the roles of T and B cells in adaptive immunity have been well studied, it remains difficult to select targets for immunotherapeutic strategies. Because human leukocyte antigen class II (HLA-II) peptides activate CD4+ T cells and regulate B cell activation, proliferation, and differentiation, these peptide antigens represent a class of potential immunotherapy targets and biomarkers. To better understand the molecular basis of how HLA-II antigen presentation is involved in disease progression and treatment, systematic HLA-II peptidomics combined with multiomic analyses of diverse cell types in healthy and diseased states is required. For this reason, MS-based innovations that facilitate investigations into the interplay between disease pathologies and the presentation of HLA-II peptides to CD4+ T cells will aid in the development of patient-focused immunotherapies.
免疫疗法通过选择性调节患者的免疫反应来治疗疾病。虽然 T 细胞和 B 细胞在适应性免疫中的作用已经得到了很好的研究，但仍然难以选择免疫治疗策略的靶点。由于人类白细胞抗原 II 类 (HLA-II) 肽激活 CD4+T 细胞并调节 B 细胞的激活、增殖和分化，这些肽抗原代表了一类潜在的免疫治疗靶点和生物标志物。为了更好地理解 HLA-II 抗原呈递如何参与疾病进展和治疗的分子基础，需要对健康和患病状态下不同细胞类型的 HLA-II 肽组学进行系统研究，并结合多组学分析。因此，基于 MS 的创新技术将有助于研究疾病病理与 HLA-II 肽向 CD4+T 细胞呈递之间的相互作用，从而有助于开发以患者为中心的免疫疗法。
Zotero 插件
